(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 June 2008 (05.06.2008)

PCT

(10) International Publication Number
WO 2008/065543 A3

(51) International Patent Classification:
C12N 15/62 (2006.01) *A61K 38/17* (2006.01)
A61K 47/48 (2006.01) *C07K 14/71* (2006.01)
C07K 14/47 (2006.01)

(21) International Application Number:
PCT/IB2007/004354

(22) International Filing Date:
28 November 2007 (28.11.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
06291824.8 28 November 2006 (28.11.2006) EP
07290042.6 11 January 2007 (11.01.2007) EP

(71) Applicant *(for all designated States except US)*: **CENTELION** [FR/FR]; 72-92 rue Léon Geffroy, F-94400 Vitry-sur-Seine (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **NESBIT, Mark** [GB/FR]; c/o Sanofi-aventis, 174 avenue de France, F-75013 Paris (FR). **CAMERON, Béatrice** [FR/FR]; c/o Sanofi-aventis, 174 avenue de France, F-75013 Paris (FR). **BLANCHE, Francis** [FR/FR]; c/o Sanofi-aventis, 174 avenue de France, F-75013 Paris (FR). **SORDELLO, Sylvie** [FR/FR]; c/o Sanofi-aventis, 174 avenue de France, F-75013 Paris (FR). **NICOLAZZI, Céline** [FR/FR]; c/o Sanofi-aventis, 174 avenue de France, F-75013 Paris (FR). **TROMBE, Marc** [FR/FR]; c/o Sanofi-aventis, 174 avenue de France, F-75013 Paris (FR).

(74) Agent: **BOUVET, Philippe**; sanofi-aventis, Département Brevets, 174 avenue de France, F-75013 Paris (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*
— *the filing date of the international application is within two months from the date of expiration of the priority period*

(88) Date of publication of the international search report:
14 August 2008

(54) Title: MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS WITH IMPROVED BIOLOGICAL ACTIVITY

(57) Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.

WO 2008/065543 A3